<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Hugo Engel on Medium]]></title>
        <description><![CDATA[Stories by Hugo Engel on Medium]]></description>
        <link>https://medium.com/@hugo.b.engel?source=rss-b82652d1d670------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*MYuodXQ12-ICkG-Vjgh-TQ.jpeg</url>
            <title>Stories by Hugo Engel on Medium</title>
            <link>https://medium.com/@hugo.b.engel?source=rss-b82652d1d670------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Wed, 18 Nov 2026 07:49:02 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@hugo.b.engel/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[My Big Fat LEON Wedding]]></title>
            <link>https://medium.com/@hugo.b.engel/my-big-fat-leon-wedding-6f4deef84c04?source=rss-b82652d1d670------2</link>
            <guid isPermaLink="false">https://medium.com/p/6f4deef84c04</guid>
            <category><![CDATA[innovation]]></category>
            <category><![CDATA[technology]]></category>
            <category><![CDATA[covid19]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[restaurant]]></category>
            <dc:creator><![CDATA[Hugo Engel]]></dc:creator>
            <pubDate>Fri, 13 Jan 2023 09:54:58 GMT</pubDate>
            <atom:updated>2023-01-13T09:58:47.283Z</atom:updated>
            <content:encoded><![CDATA[<h3>I got married 3 years ago.</h3><p><em>But it wasn’t a Tuscan wedding with the partner of my dreams.</em></p><p>In fact, I didn’t know I was getting married until I arrived at work to find what is normally LEON’s training school / Wing Chun studio transformed into a wedding venue and co-founder John Vincent barefoot in a cassock.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/634/1*M2ac5qlut6URODxV0RCfhw.jpeg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/449/1*JoTOoNSAx2Wbsu6iNMz97A.png" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/736/1*2H-8rAlB2ATOzQ0cNPCvTw.jpeg" /><figcaption>My big day</figcaption></figure><p>A few months earlier I had sat beside a camp-fire with John as he shared his ambitions for LEON. He had just raised funding from an investor who believed that LEON leveraging digital and data was the key to being able to rapidly scale beyond its central London heartland and truly deliver its mission of <strong>making it easier for <em>everyone </em>to eat and live well</strong>.</p><p>The challenge was that LEON was operating in an <strong>industry rated second to bottom in digital maturity</strong>. John believed it would take someone from outside hospitality to make this change and he offered me the chance lead this journey. In that moment he believed in me more than I believed in myself. But through this act he gave me the opportunity to grow.</p><h4>The Honeymoon Phase</h4><p>Over the next couple of months <strong>I <em>immersed</em> myself into the wonderfully weird world of LEON</strong>:</p><ul><li>Working in our restaurants (<em>blame me if you’ve ever had a bad muffin from London Bridge</em>)</li><li>Interviewing different teams in our Support Office</li><li>Speaking with LEON guests</li><li>Researching industry and technology trends</li><li>Visiting our US restaurants and competitors</li><li>Organising a hackathon with Imperial Design &amp; Engineering students</li><li>+ the occasional team trip to John’s house in Sussex for a wellness retreat.</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*o5T2KDzyHo1jkaoz6SLw_A.jpeg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/724/1*Bt_nUNx4AT9w8cV3BKISkQ.jpeg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*08xekDDHDkt4x0zkQQVvWw.jpeg" /></figure><p>All this provided me with what I now know as <em>‘human-centric understanding’</em> and, with this foundation, we were able to begin defining the <strong>LEON experience of the future and the value it would unlock</strong>. However the nascent stage of the digital ecosystem in our sector (pre-COVID) meant that the technology platforms required to deliver this vision didn’t yet exist.</p><p><em>[Enter Vita Mojo, stage right]</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*jDaPNbv6i-ltmnuZ.png" /><figcaption>Nick &amp; Stefan, Vita Mojo Co-Founders</figcaption></figure><p>An early-stage software start-up had identified the same problem and were developing a digital ordering platform by running two real restaurants as covert test labs for rapid feedback and iteration. <strong>It was love at first sight.</strong></p><p>Their platform was in its infancy but this provided the opportunity to form <strong>a close-knit partnership where we could shape their product strategy so that we could win together</strong>. Most importantly, their team, culture and product vision suggested that they could successfully disrupt the slow-moving-hardware-native-restauant-tech incumbents to whom user experience always felt like an after-thought. We decided to run a pilot in a LEON restaurant as quickly as possible.</p><p>This was around the time of the wedding. The Vita Mojo co-founder - Nick Popovici - walked me down the aisle. My bride? The digital transformation program that this pilot marked the beginning of. <strong>The wedding was John’s way of clarifying project accountability whilst having some fun at the same time (<em>because, why not?</em>)</strong></p><h4>Unexpected Turbulence</h4><p>This was also the start of 2020 when<strong> I thought I had built a nice roadmap</strong> of how to deliver this transformation via the agile development of the key pillars of the new model in pilot restaurants. By the end of March 2020, <strong>that roadmap was in the bin</strong> and we were standing in a room with sticky notes <strong>trying to work out what a restaurant business does when restaurants are shut down by a global pandemic</strong>.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*i8mMC2iMbWut4EyX1i_NTQ.png" /></figure><p>John encouraged us to<strong> focus on our purpose </strong>— making it easier for everyone to eat and live well — and the answer became clear:</p><ol><li>We turned restaurants into shops</li><li>We fed NHS workers for free</li><li>We set up ‘Feed Britain’.</li></ol><figure><img alt="" src="https://cdn-images-1.medium.com/max/900/0*DKkPH-5GFTuW1LH8.jpg" /></figure><figure><img alt="" src="https://cdn-images-1.medium.com/max/600/0*QahQcRUgorwwnShK" /><figcaption>Feed Britain and Feed the NHS</figcaption></figure><p>Morning calls were now with Damian Lewis and Matt Lucas who were helping us raise money for our FeedNHS campaign (anyone remember the <a href="http://youtube.com/watch?v=yYOkgCkxj9I">the Baked Potato song</a>?!).<strong> </strong>I was working on building ‘Feed Britain’: a D2C e-commerce venture to link restaurant suppliers (who had lost all their customers) with consumers who could no longer easily access food in supermarkets <a href="https://www.shopify.com/uk/enterprise/hugo-engel-on-leon-covid-19-pivot-with-feed-britain">(read more here)</a>. We all worked all weekends. <strong>I discovered that purpose and culture eat strategy for breakfast</strong>. We fed <a href="https://www.damian-lewis.com/2020/10/29/37432.php">40,000</a> free hot healthy meals per day to NHS workers.</p><h4>Building our future</h4><p><strong>Throughout the year we continued to develop the new tech-enabled restaurant model in several sites via a test-and-learn approach.</strong> COVID had removed the fear of change: suddenly everything was possible. I spent most days working remotely from our pilot restaurants where there was a blitz-spirit amongst the team — they would come in on their days-off just to socialise and support each other. I learnt a huge amount from just being around them and our guests.</p><p><strong>But these ‘connected’ restaurants were also amassing much richer customer and operational data that we weren’t fully harnessing.</strong> Fortunately the team working on ‘Feed Britain’ had now experienced how connecting transactions to known, contactable customers had the potential to superpower their decision-making. I had the crucial cultural buy-in to do the same for our restaurant business. But to deliver this would require a transformation of our whole data architecture, marketing and BI platforms — all at the same time that the business was haemorrhaging cash.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*TJ5nTXtWiDSPsIHc" /><figcaption>Vishal Sharma</figcaption></figure><h4>Meeting the in-laws</h4><p>Around this time we met with <a href="http://bbc.co.uk/news/business-54343391">the Issa brothers</a>, sitting in one of their Starbucks drive-thrus on a rainy Saturday. I shared the results we had seen in the growing number of digitally-enabled restaurants. They understood the potential of this model to scale outside central London and give the choice of better fast-food to people who had never seen a LEON before.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/650/1*VTOqd_9s6GoQI3bldgD6Gw.png" /><figcaption>Mohsin Issa CBE and Zuber Issa CBE, co-founders and co-CEOs, EG Group,</figcaption></figure><p>In April 2021,<strong> John managed to secure an exit to EG Group</strong>. In the handover call to the Issa brothers, John declared:</p><blockquote>‘The king is dead, long live the kings!’</blockquote><p>This was another twist that I didn’t expect at the start of my LEON journey. It was difficult to see LEON people that I admired leave during this time and, at times, challenging to navigate the organisational change that an acquisition inevitably involves. However <strong>there was clearly an opportunity, with EG’s financial backing, to rapidly scale everything we had worked towards.</strong> So I made frequent trips to EG Group’s Blackburn HQ and found support for the project. The roll-out demanded learning a different skill-set from the earlier innovation phase but I was keen to finish what I’d started.</p><p>The restaurant transformation wasn’t just customer-facing, <strong>we had also re-engineered the team experience and how they manage the order preparation process </strong>in partnership with Centegra. <a href="https://centegra.co.uk/customer-stories/leon/">Centegra </a>and <a href="https://www.adyen.com/en_GB/blog/leon">Adyen </a>proved particularly invaluable partners over the coming months, as we battled supply chain challenges during the global chip shortage, to install the hardware needed to scale the new restaurant model throughout our estate and then subsequently into the new regional openings.</p><p>I sometimes missed the creative aspect of the initial phases and so channeled that energy into<strong> other new LEON ventures such as our </strong><a href="https://www.bighospitality.co.uk/Article/2021/06/28/Leon-plans-first-drive-thru-restaurant-as-it-prepares-for-accelerated-UK-expansion"><strong>first drive-thru</strong></a><strong>, </strong><a href="http://bighospitality.co.uk/Article/2020/09/09/Leon-to-launch-unlimited-coffee-offer"><strong>digital coffee subscription</strong></a><strong>, </strong><a href="http://thebusinessdesk.com/northwest/news/2106395-leon-to-more-than-double-its-self-serve-coffee-kiosks-in-asda-and-forecourts"><strong>self-service coffee kiosks</strong></a>, <strong>and the </strong><a href="https://www.thegrocer.co.uk/technology-and-supply-chain/leon-launches-points-based-loyalty-app/664561.article"><strong>LEON mobile app</strong></a>. Vishal and I were also working to leverage the new cloud data architecture to get data insights into the hands of the restaurant team so that they could access the e-commerce level customer insights that were new territory for our industry.</p><h4>The break-up</h4><p>Paul Simon observed that there are <a href="https://open.spotify.com/track/6Qb7gtV6Q4MnUjSbkFcopl?si=bdb81f1843a042c3">fifty ways to leave your lover</a> but I nevertheless thought long and hard about leaving LEON after we had shared so much together. Early in 2022, with the digital transformation now scaled throughout the business, I felt like the marriage had come to its natural end.</p><h4><strong>What next:</strong></h4><ul><li><strong>EG Group are using the new digitally-enabled restaurant model to </strong><a href="http://thegrocer.co.uk/finance/leon-accelerates-store-rollout-programme-with-50-new-restaurants/663048.article"><strong>2x the LEON estate</strong></a></li><li><a href="https://www.linkedin.com/in/vishal-sh/"><strong>Vishal</strong></a><strong> leads Data Science at EG Group</strong></li><li><strong>In June 2022, Vita Mojo </strong><a href="https://news.sky.com/story/restaurant-software-developer-vita-mojo-gets-battery-charge-with-30m-funding-12642345"><strong>raised £30m</strong></a><strong> from Battery VC to supercharge their expansion across Europe (</strong><a href="https://careers.vitamojo.com/#jobs"><strong>they’re hiring…</strong></a><strong>)</strong></li><li><strong>I joined </strong><a href="http://accenture.com/us-en/about/accenture-song-index"><strong>Accenture Song</strong></a><strong> where I work to define and design innovative growth opportunities for global clients</strong></li></ul><p><em>I have used ‘we’ throughout this account in its truest sense: all of the above was made possible by the hard-work of the LEON team and our partners that I learnt so much from.</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/proxy/1*BsDx8RGbLG-X9VGwxY2IHQ.jpeg" /></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=6f4deef84c04" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How a Startup is Using Magic Mushrooms to Treat Depression]]></title>
            <link>https://medium.com/@hugo.b.engel/following-compass-ae93fab80cad?source=rss-b82652d1d670------2</link>
            <guid isPermaLink="false">https://medium.com/p/ae93fab80cad</guid>
            <category><![CDATA[pharmaceutical]]></category>
            <category><![CDATA[mental-health]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[drugs]]></category>
            <category><![CDATA[psychedelics]]></category>
            <dc:creator><![CDATA[Hugo Engel]]></dc:creator>
            <pubDate>Thu, 31 Jan 2019 16:44:53 GMT</pubDate>
            <atom:updated>2019-02-01T17:06:04.010Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*W66MrFmgYXEOr-BClGTThw.jpeg" /><figcaption>The married COMPASS Pathways co-founders: George Goldsmith and Katya Malievskaia</figcaption></figure><p>This is a story about depression; magic mushrooms; and a married couple building a billion dollar pharmaceutical startup.</p><p><strong>Depression is the single leading cause of disability worldwide </strong><em>(Source: WHO)</em>. The total costs of mental health issues amount to more than 4% of GDP across the EU <em>(Source: OECD)</em>. These are the sort of figures that fire up policy-makers. But it was an event much closer to home that moved the married co-founders of <em>COMPASS Pathways</em> to action. George Goldsmith and Katya Malievskaia’s son had developed severe depression. The standard bundle of antidepressant drugs and cognitive behavioural therapy (CBT) just wasn’t working. This isn’t unusual: one-third of depressed patients are considered ‘treatment-resistant’, and their son was one on them. Katya, a doctor in internal medicine and expert in public health, was up late at night scouring academic journals for potential solutions when she came across small-scale research that pointed to the therapeutic potential of psilocybin.</p><p><strong>Psilocybin is the psychedelic ingredient in magic mushrooms.</strong> Indigenous cultures have been benefiting from the use of magic mushrooms for centuries. But it wasn’t until the discovery of LSD in the mid-20th Century that Western cultures started experimenting with psychedelic drugs. These substances quickly became strongly associated with the counterculture movements of the 60s, particularly the anti-Vietnam war protests, and it wasn’t long until they were banned under national laws and international conventions as part of the disastrous ‘War on Drugs’.</p><p>The effect of this legislation for medical and life sciences research was <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307971/">devastating</a>. Scientists around the world attempting to investigate the clinical potential of these particular molecules faced an impenetrable jungle of burdensome and costly regulations which forced almost all research to come to a halt for half a century.</p><p>Psilocybin naturally occurs in over 200 species of mushroom. However, researchers are required to artificially synthesise their own pure psilocybin in order for it to be of adequate quality for medical use.</p><p>In the last decade, commentators have been hailing a <strong>‘psychedelic renaissance’</strong> as new brain-imaging technology and the assistance of crowd-funded non-profit organisations, most notably <a href="https://maps.org/">MAPs</a>, have enabled scientists to gain insights into the therapeutic potential of these banned substances that have exceeded all expectations. New ‘fMRI imaging’ techniques have allowed scientists to better understand what the ‘psychedelic state’ actually looks like in the brain and patient trials have indicated that psilocybin therapy could be more effective than the treatments for depression currently on the market.</p><p>George and Katya founded <em>C.O.M.P.A.S.S.</em> in 2015 as one such non-profit organisation with the mission of aiding the development of psilocybin for therapeutic use. After a successful but small-scale project on the Isle of Man, they came to realise that the regulatory burden was such that their capacities to reach patients as a non-profit were severely limited. It was after a particularly frustrating 4 hour meeting with the <em>European Medicines Agency</em>, attended by renowned expert in the field, Prof. David Nutt, that they decided to pivot into a pharmaceutical startup. They welcomed business school grad and serial entrepreneur <a href="https://compasspathways.com/member/lars-wilde/">Lars Wilde</a> onto the founding team and set about raising capital for <em>Compass Pathways</em>.</p><p>They are clearly an impressive team: in addition to <a href="https://compasspathways.com/member/ekaterina-malievskaia/">Katya’s</a> scientific background, <a href="https://compasspathways.com/member/george-goldsmith/">George</a> is a serial entrepreneur who specialises in helping businesses negotiate with regulators. But it must have been a struggle to convince investors to pour their money into a notoriously risky sector where even the most accomplished founders are completely dependent on the success of future clinical studies. Perhaps it was their personal story or Silicon Valley’s penchant for psychedelics that helped them raise almost <a href="https://www.crunchbase.com/organization/compass-pathways/funding_rounds/funding_rounds_list#section-funding-rounds"><strong>$40M</strong></a>.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*c2OY-pueEQhmWKqlkbtxLA.jpeg" /><figcaption>Peter Thiel (Co-founder of Paypal, First Outside Investor in Facebook, Founder of Palantir)</figcaption></figure><p>Their investors include the infamous Paypal co-founder Peter Thiel; the Wall Street-turned-crypto financier Mike Novogratz and various European VCs. The magic mushroom had hit the mainstream and they now had the necessary funding to synthesise their own psilocybin and roll out detailed clinical trials in the UK, the Netherlands, Finland, Portugal and the US on the use of psilocybin for treatment-resistant depression.</p><h4><strong>What can a patient expect from psilocybin therapy?</strong></h4><p>Unlike <strong>anti-depressant medication </strong>(e.g. SSRIs), the patient is not left to self-administer psilocybin. But unlike <strong>cognitive behavioural therapy </strong>(CBT), the psilocybin sessions are completely non-directive.</p><p>If you were a patient receiving psilocybin therapy, you would meet with a therapist a few weeks before your trip in order for you to get to know each other and mentally prepare for what is likely to be an intensely strange experience. The trip itself takes place in a room with soft-furnishings and a high-fidelity sound system playing fairly neutral music (think <a href="https://www.youtube.com/watch?v=M73x3O7dhmg">Phillip Glass</a>). The same therapist is on-hand to gently guide the patient and encourage them to remain open to the experience, but is not there to engage in any sort of intellectual conversation. One <a href="https://itunes.apple.com/gb/podcast/64-researching-psilocybins-effects-on-depression-dr/id1236907421?i=1000406433200&amp;mt=2">therapist</a> likens the role to a mid-wife compassionately reassuring a mother giving birth. And, like giving birth, patients report that their trip to be one of the most meaningful and profound experiences in their life.</p><p>This contrasts with the role of the cognitive behavioural therapist who, through Socratic conversation, acts as the expert directing the patient towards the answer. <strong>In psilocybin therapy, the patient is their own expert.</strong> After the treatment, patients <a href="https://journals.sagepub.com/doi/abs/10.1177/0022167817709585">report</a> feeling like their brain has been rebooted and that their constant spiral of ruminating thought-loops was temporarily replaced with a heightened consciousness filled with beautiful chaos that showed them how to escape the negative self-narration that had imprisoned their mind.</p><h4><strong>So what is actually happening in the brain?</strong></h4><p>Psilocybin has been shown to reduce blood flow to the <strong>Default Mode Network (DMN)</strong>. The DMN is a busy transport hub that connects different parts of your brain to create what you perceive as your standard state of <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909994/">consciousness</a>. As we develop from young children into adults, these neural connections grow stronger but also more constrained. This is why children can come out with strange but creative ways of seeing the world — their brains are more plastic and free to make unusual connections — whereas adults tend to become more fixed in their thinking. In the psychedelic state, the DMN is suppressed causing the brain to reorganise its usual network of neural links into a fresh state of <strong>‘</strong><a href="https://royalsocietypublishing.org/doi/pdf/10.1098/rsif.2014.0873"><strong>hyperconnectivity</strong></a><strong>’</strong> where new and unusual connections are formed between different parts of the brain. This is analogous to bringing us back to a <a href="https://www.youtube.com/watch?v=FyAgx_tzh80">more free, child-like state of consciousness</a>.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/570/1*yWh8ooxu2a7huZpckPxN8g.jpeg" /><figcaption>Functional connectivity of the brain on placebo (a) compared to on psilocybin (b). There is no increase in the number of neural connections but the connections in the psychedelic state are much less constrained (hyperconnectivity).</figcaption></figure><p>Depressed patients are trapped in a rut of negative thoughts and, like tracks in the snow, the more they ruminate, the stronger those connections get and so the deeper the ruts become. <strong>Psilocybin, by temporarily suppressing the DMN, acts like a snow-plough smoothing over those deep-cut tracks allowing the patient’s mind to escape the rut of depression and roam freely through previously unexplored thoughts and emotions.</strong></p><p>The DMN is also very much involved in maintaining your sense of self, your ego — that narrative voice inside your head which separates you from the rest of the world. For depressed patients, that inner voice of the ego is often pernicious and over-active. CBT and mindfulness therapy aims to combat this by encouraging patients to identify less with their thinking and emotions. However, this is a difficult and resource-intensive process. The sense of the shrinking of your own ego — accompanied by a growing feeling of interconnectedness with a universal tapestry of consciousness — has long been reported by users of psychedelics however it is only now that we are beginning to understand the mechanism and its therapeutic potential. <strong>The ego-dissolving effects of psilocybin can help patients gain a sense of inner peace which stays with them after the hallucinogenic effects have worn off and achieve</strong><a href="https://youtu.be/8kfGaVAXeMY?t=604"><strong> in a matter of hours what takes months</strong></a><strong> in talking therapy.</strong></p><p>The amygdala is a small, almond-shaped part of your brain responsible for processing negative emotions such as stress and fear. Traditional SSRI antidepressants operate by reducing the response of the amygdala to negative emotions, which some have observed causes an unwanted side-effect of ‘emotional blunting’ in patients. Scientists were surprised to find that amygdala responsiveness was increased post-psilocybin. This has led them to <a href="https://www.sciencedirect.com/science/article/pii/S0028390817306391">hypothesise</a> that, whilst antidepressants could reinforce emotional disconnection, <strong>psilocybin therapy led patients to confront and work through all emotions — accepting the negative ones as well as having a greater appreciation for the good times.</strong></p><h4><strong>Success and Controversy</strong></h4><p><em>COMPASS</em> has demonstrated sufficient preliminary clinical evidence that psilocybin may be a substantial improvement over available therapy for treatment-resistant depression for the <em>US Food and Drug Administration (FDA)</em> to designate them a <strong>‘Breakthrough Therapy’</strong>. This means that <strong>the </strong><a href="https://www.fda.gov/regulatoryinformation/lawsenforcedbyfda/significantamendmentstothefdcact/fdasia/ucm329491.htm"><strong><em>FDA</em></strong></a><strong> will assist <em>COMPASS</em> by accelerating the clinical development</strong> of their product.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*r-E6VT587JdvbuDN2lq4SQ.jpeg" /><figcaption>Compass’ Critics</figcaption></figure><p>However, the mainstream success of <em>COMPASS</em> has put it at loggerheads with many in the psychedelic community. Soon after the FDA designation, Quartz published an <a href="https://qz.com/1454785/a-millionaire-couple-is-threatening-to-create-a-magic-mushroom-monopoly/">article</a> detailing allegations that <em>COMPASS</em> had been <strong>misleading its researchers; </strong>putting<strong> patient safety at risk </strong>in their rush to go to market<strong>; </strong>and adopting the <strong>worst kind of pharmaceutical-industry tactics </strong>in order to dominate the field. The piece cited the concerns of <strong>9 psilocybin experts</strong> who had previously worked with <em>COMPASS</em> in its non-profit form but now felt deeply betrayed by its corporate approach. This article quickly spread amongst those passionate about psychedelics. For most readers this was the first time they had come across <em>COMPASS</em> and the picture it painted of “a millionaire couple threatening to create a magic mushroom monopoly” was enough to persuade many of them that selfish elites were once again trying to ruin the party. <em>COMPASS</em> are a startup — they don’t yet have a communications department — and the tone of their two written statements in response which claimed that their critics were “malicious[ly] bias[ed]” seemed ineffective at adequately rebutting the specific allegations made against them and only confirmed to many readers that they were the bad guys.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*6Qu3OEstraTT5WR6HhoITg.jpeg" /><figcaption>George, Katya and Lars at the student event</figcaption></figure><p>Coincidentally, it was at an event organised by the <em>LSE Neuroscience Society</em> and the <em>UCL Society for the Application of Psychedelics</em> where the co-founders of <em>Compass</em> publicly responded to these allegations for the first time.</p><p>Here they were able to tell the complete story outlined above of how and why <em>COMPASS</em> became a for-profit business. Katya also argued that, given how much it costs to take the treatment to market (£100M — £200M), there is an ethical issue of taking so much funding from the charity sector when it could be sourced from investors.</p><p>They also defended their use of patents which has been criticised as intentionally monopolistic in restricting others’ access to their research. They pointed out that patents are necessary to secure the funding needed to bring a drug to market and explained that the patent is only on the process of synthesising the psilocybin they are using (<em>COMPASS</em> created about 60 new solutions to problems with synthesising psilocybin). They also highlighted that there is a time limit on these patents — in Europe the patent prohibits another company selling <em>COMPASS</em>’ psilocybin synthesis only for 10 years (and other organisations can begin to use data from their research after 8 years). Furthermore, it does not prohibit any other enterprise from initiating the development of their own psilocybin treatment based on a different synthesis to <em>COMPASS</em>’. The couple stressed that they will prioritise patient access, extracting profits from selling the treatment at a high volume rather than at a high price.</p><h4><strong>The Direction of Compass</strong></h4><p>Lars Wilde, COO, gave an timeline of 3–5 years before their treatment is rolled out. This is ambitious but will tragically still be too late for many depressed patients. It will be interesting to see which market they choose to enter first — will they choose whichever country grants them approval first or wait to launch in a smaller test market before expanding to the US?</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*dFNL4S3DDUkETJLiVkAVGA.jpeg" /><figcaption>George meeting a queue of UCL and LSE students</figcaption></figure><p>One of the biggest challenges they face will be training enough therapists in a practice very different from traditional CBT. However the hoards of students at <em>UCL</em> jostling for the chance to introduce themselves and exchange business cards with the founders was a positive indication of strong interest from a new generation of talented graduates.</p><p>The backlash <em>COMPASS</em> faced from the psychedelic community at their signs of success is undoubtedly only the beginning. If <em>COMPASS</em> further progresses through the necessary regulatory hoops, they will surely attract more mainstream media scrutiny. In spite of the scientific evidence to the contrary, it will likely prove too tempting for many newspapers to take a cheap shot at ‘the couple looking to poison our kids with their hippie-dippie shrooms’. It may be advisable for them to hire a full-time Head of Communications.</p><p>They will also face the challenge of big pharma who will do everything in their power to stop a competitor taking a slice from the sizeable anti-depressant pie. Of course, this could ultimately be <em>COMPASS</em>’ exit strategy. 15 years down the line, it could be hard for them to persuade their investors (or indeed themselves) that they should refuse a multi-billion dollar offer from an incumbent.</p><p>The nature of the sector is such that it is tempting to assert that, in 10 years time, <em>COMPASS</em> will either be a billion dollar company that has used an ancient psychedelic compound to transform lives or simply end up as Thiel’s risky investment gone wrong. Whichever it is to be, the results from the ground-breaking research that <em>COMPASS</em> is conducting will ultimately be to the benefit of all of us. A fluke of political censorship means that this still is a very new area of research and <em>COMPASS</em> is at its forefront. Such an untapped territory is likely to contain many unknown unknowns. Perhaps <em>COMPASS</em> will guide the way to some unlikely discoveries which could have much wider societal implications for our understanding of consciousness. In any case, I’ll try to keep you updated about about <em>COMPASS</em>’ journey! <strong>Turn on — Tune In…</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/599/1*Avo2zBl0wif5o2vqybwTxg.jpeg" /></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ae93fab80cad" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>